A new claims-data analysis of hidradenitis suppurativa (HS) reported by Dermatology Times points to two findings that should reshape how dermatology practices think about the disease: roughly equal representation of men and women in the claims record, and a measurable gap in care for patients in rural areas.

The headline result — sex parity — cuts against a long-standing clinical assumption. HS has been characterized for years as a disease that predominantly affects women, with textbook ratios often cited in the range of two to four female patients for every male. The claims analysis, as summarized by Dermatology Times, suggests that in real-world insurance data the sex distribution is far more balanced than referral-based and specialty-clinic cohorts have implied.

The second finding is geographic. Patients in rural areas face barriers to HS care that their urban counterparts do not, a disparity the analysis frames as a rural care gap. For a disease that requires surgical, medical and procedural management — often coordinated across dermatology, general surgery and emergency settings — distance from a specialist is not a trivial inconvenience. It is a structural determinant of when patients get diagnosed, what stage they have reached by that point, and which treatments they can realistically access.

Why does the sex-parity finding matter?

Cohort selection explains much of the discrepancy. Specialty dermatology clinics and surgical referral centers tend to capture patients with more advanced or more visible disease, and referral patterns can skew female. Claims databases, by contrast, capture a broader slice of the insured population — primary-care visits, emergency-department encounters, procedural claims — and therefore paint a more representative epidemiological picture.

For clinicians, the practical implication is straightforward: HS should sit high on the differential for men presenting with recurrent boils, axillary or inguinal nodules, and scarring follicular lesions, not only for women. Under-recognition in male patients is a documented problem in the HS literature, and a claims-level confirmation of near-parity reinforces the need to lower the diagnostic threshold across sexes.

It also matters for trial design and market sizing. If the true treated population approaches sex parity, prevalence estimates and commercial projections built on a female-skewed assumption will underserve — and undercount — male patients.

What does the rural care gap change in practice?

The rural finding speaks directly to access. HS management is resource-intensive: biologic therapy requires prior authorization and monitoring, Hurley stage II–III disease often needs wide local excision or deroofing, and follow-up intervals are short relative to many chronic skin diseases. Each of those demands multiplies in difficulty when the nearest dermatologist is hours away.

Claims data of this kind help quantify the problem, because they show where diagnoses and procedures actually occur — and, by omission, where they do not. A rural patient who appears in the claims record only through emergency-department visits for incision and drainage, without an HS diagnosis code or a specialist claim, is the archetype of the gap the analysis describes.

Practices serving mixed urban-rural catchments can act on this in concrete ways:

• Extend visit intervals with structured telehealth follow-up for stable biologic patients
• Partner with rural primary-care clinics on HS recognition and coding, so patients enter the system with a correct diagnosis
• Track no-show and travel-distance data for HS patients specifically, since this cohort carries one of the highest attrition burdens in dermatology

What are the limits of claims data?

Claims analyses carry well-known constraints, and this one is no exception. Coding accuracy for HS is imperfect; milder disease, particularly in patients managed with incision and drainage in emergency settings, may be miscoded or missed entirely. Insurance claims exclude the uninsured, who are overrepresented in rural regions — which means the rural gap the analysis detects could, if anything, understate the true disparity.

Sex parity in claims also reflects the treated population, not necessarily the diseased population. If men access care at lower rates but those who do generate equal claim volume, the underlying epidemiology could still differ from the claims picture. The Dermatology Times summary does not resolve that question, and clinicians should read the parity finding as a signal about who is showing up in the data rather than a definitive statement about population prevalence.

The bottom line

Two practice-level conclusions emerge. First, treat HS as a disease of both sexes in the exam room and in screening conversations — the claims record does not support a heavy female skew. Second, treat geography as a clinical variable: for rural patients, the care plan that works on paper may fail in practice unless access is engineered into it.

As claims databases grow richer and linkage to pharmacy and procedural records improves, expect sharper quantification of both the sex distribution and the rural access gap — and, with it, stronger evidence for which interventions actually close that gap.